Merck & Co. Inc. (NYSE:MRK) has signed two licensing contracts for investigational HIV drug candidates. In addition, the firm reported plans to begin a Phase II evaluation for a proprietary investigational next generation non-nucleoside reverse transcriptase inhibitor, MK-1439, and okayed a deal with Chimerix Inc. based in Research Triangle Park, North Carolina, for CMX157, which is an investigational oral nucleoside reverse transcriptase inhibitor that is currently in Phase I clinical development. Separately, the company signed an contract with Yamasa Corporation, to develop EFdA, a new nucleoside reverse transcriptase inhibitor candidate that is in preclinical studies and has shown antiviral activity toward highly resistant HIV strains. This candidate was discovered jointly with a group which is led by the HIV research scientist Dr. Hiroaki Mitsuya of Kumamoto University’s Center for AIDS Research in Japan.
Microsoft Corporation (NASDAQ:MSFT): Twitter’s chief executive has described a plan that should make the firm more useful for a broader range of social media actions. The scheme, when operational, will likely move Twitter into a more direct conflict with groups that have before been their allies, says the Wall Street Journal.
Pfizer Inc. (NYSE:PFE) has issued a top-line result in the first of four Bapineuzumab Phase 3 studies, which were conducted by Pfizer and Janssen AI, according to a statement released Monday night by Elan Corporation (NYSE:ELN). The announcement referenced Study 302, which is the first of four placebo-controlled Phase 3 studies to complete a comprehensive development program of bapineuzumab IV. Elan acquired a 49.9 percent stake in Janssen AI in September 2009, as a result of its transaction with Johnson & Johnson,
Procter & Gamble Company (NYSE:PG) and the United States Environmental Protection Agency National Risk Management Research Laboratory have signed a Cooperative Research and Development Agreement through which new tools to optimize sustainability, improvements in manufacturing facilities, and their associated supply chains, will be developed. The term of this Agreement is 5 years.
Don’t Miss: Cisco Gets Thumbs-Up For This HUGE BUY.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.